Compare Quest Diagnostics Inc (DGX) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Oatly Group AB - ADR — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Oatly Group AB - ADR trades at $10.59 (market cap $330.93M). The key difference: Quest Diagnostics Inc is far larger — about 77× Oatly Group AB - ADR's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Oatly Group AB - ADR for 18 Days on average.
| DGX | OTLY | |
|---|---|---|
Market Cap | $25.48B | $330.93M |
Volume | 941,866 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $247.45 | $15.91 |
52-Week Low | $173.49 | $8.03 |
Typical Hold Time | 56 Days | 18 Days |
Enterprise Value | $31.23B | $835.34M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
OTLY trades at $10.38 with minimal daily movement (+0.1%). The stock shows mixed signals with a bearish technical outlook but improving fundamentals. Recent Q2 2026 results showed revenue growth and margin improvement, though the company continues to post net losses. Analyst sentiment is divided with a $12.28 consensus target, representing 18% upside potential from current levels.
The investment case hinges on Oatly's ongoing turnaround efforts showing progress through revenue growth and margin expansion. Key risks include persistent negative cash flow, high debt levels, and delayed profitability. The stock offers speculative appeal for investors betting on the plant-based beverage market growth and operational improvements, but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
